• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

癌细胞中的有丝分裂通过高表达HLA-G和PD-L1增加免疫抗性。

Mitosis in Cancer Cell Increases Immune Resistance via High Expression of HLA-G and PD-L1.

作者信息

Ullah Matti, Aoudjeghout Warda, Pimpie Cynthia, Pocard Marc, Mirshahi Massoud

机构信息

CAP-Paris Tech., INSERM U1275, Hôpital Lariboisière, 2, rue Ambroise-Paré, 75010 Paris, France.

出版信息

Cancers (Basel). 2020 Sep 18;12(9):2661. doi: 10.3390/cancers12092661.

DOI:10.3390/cancers12092661
PMID:32961872
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7564851/
Abstract

Cancer is a result of "aggressive" division and uncontrolled proliferation of the abnormal cells that survive attack by immune cells. We investigated the expression of HLA-G and PD-L1 with the different stages of cancer cell division along with their role in the interaction of immune cells in vitro. Ovarian cancer (OVCAR-3) and chronic myeloid leukemia cell line (K-562) are used for this study. The correlation of protein expression with percentage of cells in each phase (G1, S and G2 phase) was evaluated through FACS. Cells were synchronized in G1, G2 and mitotic phase to evaluate gene (RT-qPCR) and protein expression (FACS). Real-time immune cell attack (RTICA) analysis with PBMCs (peripheral blood mono-nuclear cells) and cancer cells were performed. We found that cells expressing higher levels of HLA-G and PD-L1 are mainly in G2 phase and those expressing lower levels are mainly in G1 phase. Evidently, the higher expression of the two proteins was observed when synchronized in mitotic phase as compared to low expression when synchronized in G1 phase. RTICA analysis showed the presence of HLA-G delayed the lysis of the cells. In conclusion, the cancer cell can escape from immune cells in division stage that suggests the impact of mitosis index for cancer immunotherapy.

摘要

癌症是免疫细胞攻击后存活下来的异常细胞“侵袭性”分裂和不受控制增殖的结果。我们研究了HLA-G和PD-L1在癌细胞分裂不同阶段的表达及其在体外免疫细胞相互作用中的作用。本研究使用卵巢癌(OVCAR-3)和慢性粒细胞白血病细胞系(K-562)。通过流式细胞术评估蛋白质表达与各期(G1、S和G2期)细胞百分比的相关性。将细胞同步于G1、G2和有丝分裂期,以评估基因(RT-qPCR)和蛋白质表达(流式细胞术)。对外周血单个核细胞(PBMC)和癌细胞进行实时免疫细胞攻击(RTICA)分析。我们发现,表达较高水平HLA-G和PD-L1的细胞主要处于G2期,而表达较低水平的细胞主要处于G1期。显然,与G1期同步时的低表达相比,有丝分裂期同步时观察到这两种蛋白质的表达较高。RTICA分析表明,HLA-G的存在延迟了细胞的裂解。总之,癌细胞在分裂阶段可逃避免疫细胞,这提示有丝分裂指数对癌症免疫治疗的影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc02/7564851/c2ec9a483d4e/cancers-12-02661-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc02/7564851/bbf8fa428d8e/cancers-12-02661-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc02/7564851/56244eb39c97/cancers-12-02661-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc02/7564851/46a9babc5ae0/cancers-12-02661-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc02/7564851/b1a6c77c9a15/cancers-12-02661-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc02/7564851/1b8305ddb2e7/cancers-12-02661-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc02/7564851/c2ec9a483d4e/cancers-12-02661-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc02/7564851/bbf8fa428d8e/cancers-12-02661-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc02/7564851/56244eb39c97/cancers-12-02661-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc02/7564851/46a9babc5ae0/cancers-12-02661-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc02/7564851/b1a6c77c9a15/cancers-12-02661-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc02/7564851/1b8305ddb2e7/cancers-12-02661-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc02/7564851/c2ec9a483d4e/cancers-12-02661-g006.jpg

相似文献

1
Mitosis in Cancer Cell Increases Immune Resistance via High Expression of HLA-G and PD-L1.癌细胞中的有丝分裂通过高表达HLA-G和PD-L1增加免疫抗性。
Cancers (Basel). 2020 Sep 18;12(9):2661. doi: 10.3390/cancers12092661.
2
Immune response and evasion mechanisms in lip carcinogenesis: An immunohistochemical study.在唇癌发生中的免疫反应和逃逸机制:免疫组织化学研究。
Arch Oral Biol. 2019 Feb;98:99-107. doi: 10.1016/j.archoralbio.2018.09.017. Epub 2018 Sep 29.
3
Association of Gpx1 fluctuation in cell cycle progression.细胞周期进展中 GPx1 波动的关联。
In Vitro Cell Dev Biol Anim. 2019 Feb;55(2):94-103. doi: 10.1007/s11626-018-00314-3. Epub 2019 Jan 10.
4
A Combination of Positive Tumor HLA-I and Negative PD-L1 Expression Provides an Immune Rejection Mechanism in Bladder Cancer.阳性肿瘤 HLA-I 和阴性 PD-L1 表达的组合为膀胱癌提供了免疫排斥机制。
Ann Surg Oncol. 2019 Aug;26(8):2631-2639. doi: 10.1245/s10434-019-07371-2. Epub 2019 Apr 22.
5
Mode of estrogen action on cell proliferation in CAMA-1 cells: II. Sensitivity of G1 phase population.雌激素对CAMA-1细胞增殖的作用方式:II. G1期群体的敏感性。
J Cell Biochem. 1987 Jul;34(3):213-25. doi: 10.1002/jcb.240340307.
6
Human Leukocyte Antigen Class I and Programmed Death-Ligand 1 Coexpression Is an Independent Poor Prognostic Factor in Adenocarcinoma of the Lung.人类白细胞抗原I类分子与程序性死亡配体1共表达是肺腺癌独立的不良预后因素。
J Pathol Transl Med. 2019 Mar;53(2):86-93. doi: 10.4132/jptm.2018.12.26. Epub 2019 Jan 14.
7
Identification of Programmed Death Ligand 1-derived Peptides Capable of Inducing Cancer-reactive Cytotoxic T Lymphocytes From HLA-A24+ Patients With Renal Cell Carcinoma.从 HLA-A24+ 肾细胞癌患者中鉴定能够诱导癌症反应性细胞毒性 T 淋巴细胞的程序性死亡配体 1 衍生肽。
J Immunother. 2015 Sep;38(7):285-91. doi: 10.1097/CJI.0000000000000090.
8
[Analysis of gene expression profiles in gastric cancer cell cycle].[胃癌细胞周期中的基因表达谱分析]
Zhonghua Zhong Liu Za Zhi. 2006 Aug;28(8):568-71.
9
PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors.PD-L1 表达与黑色素瘤对 MAPK 抑制剂耐药的免疫逃逸。
Clin Cancer Res. 2017 Oct 15;23(20):6054-6061. doi: 10.1158/1078-0432.CCR-16-1688. Epub 2017 Jul 19.
10
The alpha1 domain of HLA-G1 and HLA-G2 inhibits cytotoxicity induced by natural killer cells: is HLA-G the public ligand for natural killer cell inhibitory receptors?HLA-G1和HLA-G2的α1结构域可抑制自然杀伤细胞诱导的细胞毒性:HLA-G是自然杀伤细胞抑制性受体的共同配体吗?
Proc Natl Acad Sci U S A. 1997 May 13;94(10):5249-54. doi: 10.1073/pnas.94.10.5249.

引用本文的文献

1
Evaluating cell cycle- and autophagy-associated cellular accumulation of lipid-based nanoparticles.评估基于脂质的纳米颗粒在细胞周期和自噬相关的细胞内积累情况。
Nat Commun. 2025 Jul 1;16(1):5964. doi: 10.1038/s41467-025-60962-4.
2
Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2-negative metastatic breast cancer.与曲妥珠单抗联合帕妥珠单抗和多西他赛用于 HER2 阳性转移性乳腺癌的疗效和安全性:APHINITY 试验的最终分析
Cancer Immunol Immunother. 2024 Aug 6;73(10):197. doi: 10.1007/s00262-024-03782-7.
3
Programmed-cell death ligand 1 (PD-L1) expression in equine sarcoids and squamous cell carcinoma.

本文引用的文献

1
Differentiation of cancer cells upregulates HLA‑G and PD‑L1.癌细胞的分化会上调 HLA-G 和 PD-L1。
Oncol Rep. 2020 Jun;43(6):1797-1804. doi: 10.3892/or.2020.7572. Epub 2020 Apr 1.
2
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors.在非胰腺神经内分泌肿瘤患者中进行的双重抗 CTLA-4 和抗 PD-1 阻断的罕见肿瘤 II 期篮子试验(DART SWOG 1609)。
Clin Cancer Res. 2020 May 15;26(10):2290-2296. doi: 10.1158/1078-0432.CCR-19-3356. Epub 2020 Jan 22.
3
PD-L1 expression levels on tumor cells affect their immunosuppressive activity.
程序性细胞死亡配体 1(PD-L1)在马肉瘤和鳞状细胞癌中的表达。
Open Vet J. 2024 Jun;14(6):1476-1482. doi: 10.5455/OVJ.2024.v14.i6.16. Epub 2024 Jun 30.
4
Harnessing the potential of HLA-G in cancer therapy: advances, challenges, and prospects.利用 HLA-G 在癌症治疗中的潜力:进展、挑战与展望。
J Transl Med. 2024 Feb 3;22(1):130. doi: 10.1186/s12967-024-04938-w.
5
Pan-cancer evaluation of clinical value of mitotic network activity index (MNAI) and its predictive value for immunotherapy.有丝分裂网络活性指数(MNAI)临床价值的泛癌评估及其对免疫治疗的预测价值
Front Oncol. 2023 Jun 27;13:1178568. doi: 10.3389/fonc.2023.1178568. eCollection 2023.
6
Prognostic biomarker NEIL3 and its association with immune infiltration in renal clear cell carcinoma.预后生物标志物NEIL3及其与肾透明细胞癌免疫浸润的关系。
Front Oncol. 2023 Feb 2;13:1073941. doi: 10.3389/fonc.2023.1073941. eCollection 2023.
7
Construction and validation of an aging-related gene signature predicting the prognosis of pancreatic cancer.预测胰腺癌预后的衰老相关基因特征的构建与验证
Front Genet. 2023 Jan 18;14:1022265. doi: 10.3389/fgene.2023.1022265. eCollection 2023.
8
Differential Expression of PD-L1 during Cell Cycle Progression of Head and Neck Squamous Cell Carcinoma.头颈鳞状细胞癌细胞周期进程中 PD-L1 的差异表达。
Int J Mol Sci. 2021 Dec 3;22(23):13087. doi: 10.3390/ijms222313087.
9
Charged Particle and Conventional Radiotherapy: Current Implications as Partner for Immunotherapy.带电粒子与传统放射治疗:当前作为免疫治疗搭档的意义
Cancers (Basel). 2021 Mar 23;13(6):1468. doi: 10.3390/cancers13061468.
肿瘤细胞上的程序性死亡受体配体1(PD-L1)表达水平会影响其免疫抑制活性。
Oncol Lett. 2019 Nov;18(5):5399-5407. doi: 10.3892/ol.2019.10903. Epub 2019 Sep 20.
4
High Expression of HLA-G in Ovarian Carcinomatosis: The Role of Interleukin-1β.HLA-G 在卵巢转移癌中的高表达:白细胞介素-1β的作用。
Neoplasia. 2019 Mar;21(3):331-342. doi: 10.1016/j.neo.2019.01.001. Epub 2019 Feb 22.
5
What did we learn from CTLA-4 insufficiency on the human immune system?CTLA-4 缺陷对人类免疫系统有何启示?
Immunol Rev. 2019 Jan;287(1):33-49. doi: 10.1111/imr.12721.
6
Induction of cell cycle arrest and inflammatory genes by combined treatment with epigenetic, differentiating, and chemotherapeutic agents in triple-negative breast cancer.联合应用表观遗传、分化和化疗药物诱导三阴性乳腺癌细胞周期停滞和炎症基因表达。
Breast Cancer Res. 2018 Nov 28;20(1):145. doi: 10.1186/s13058-018-1068-x.
7
CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest.CDK4/6 抑制在癌症中的作用:超越细胞周期阻滞。
Trends Cell Biol. 2018 Nov;28(11):911-925. doi: 10.1016/j.tcb.2018.07.002. Epub 2018 Jul 27.
8
Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy.癌症免疫治疗中靶向CTLA-4的角色演变
Cell Physiol Biochem. 2018;47(2):721-734. doi: 10.1159/000490025. Epub 2018 May 22.
9
Anti-CTLA-4 immunotherapy: uncoupling toxicity and efficacy.抗CTLA-4免疫疗法:分离毒性与疗效。
Cell Res. 2018 May;28(5):501-502. doi: 10.1038/s41422-018-0031-9. Epub 2018 Mar 28.
10
The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade.CDK4/6 抑制剂阿贝西利诱导 T 细胞炎症肿瘤微环境并增强 PD-L1 检查点阻断的疗效。
Cell Rep. 2018 Mar 13;22(11):2978-2994. doi: 10.1016/j.celrep.2018.02.053.